General Cancer Care and Prevention Protocol

Cancer SupportModerate Evidence

supplements

Primary

Supporting

Grade A

165

Studies

Primary Stack

Core supplements with strongest evidence

Vitamin DB

2000-4000 IU daily (target 40-60 ng/mL)

Regulates cell differentiation and apoptosis; deficiency associated with increased cancer risk for multiple malignancies

All-Cause Mortality↑Breast Cancer Risk↓Cardiovascular Disease Mortality↓Colorectal Cancer Risk↑Stroke Risk

40 studies50,000 participants

Supporting Studies (2)

PMID: 30415629 - VITAL trial: Vitamin D and cancer incidence (2019)PMID: 31405204 - Vitamin D and cancer prevention: meta-analysis (2019)

Omega-3 Fatty AcidsB

2-4g EPA/DHA daily

Anti-inflammatory and may inhibit tumor cell proliferation; supports healthy weight maintenance during treatment

30 studies20,000 participants

Supporting Studies (1)

PMID: 32025599 - Omega-3 and cancer outcomes: systematic review (2020)

Supporting Stack

Additional supplements for enhanced results

CurcuminB

500-2000mg daily (enhanced absorption formula)

Multi-targeted anticancer effects: inhibits NF-κB, induces apoptosis, inhibits angiogenesis and metastasis

25 studies2,000 participants

Supporting Studies (1)

PMID: 25818808 - Curcumin in cancer prevention and treatment: review (2015)

Green Tea Extract (EGCG)B

300-600mg EGCG daily

EGCG inhibits tumor growth pathways, induces apoptosis, and has antiangiogenic properties

20 studies3,000 participants

Supporting Studies (1)

PMID: 26092765 - Green tea catechins and cancer prevention: meta-analysis (2015)

Medicinal Mushrooms (Reishi, Turkey Tail)B

1-3g extract daily (standardized to beta-glucans)

Beta-glucans enhance immune surveillance; may improve quality of life and immune function during cancer treatment

↑Immunity↑Natural Killer Cell Activity↓TNF-Alpha

15 studies1,000 participants

Supporting Studies (1)

PMID: 22972060 - Reishi mushroom for cancer: Cochrane review (2012)

SeleniumC

100-200mcg daily (do not exceed)

Essential for glutathione peroxidase; selenoproteins have antioxidant and potential anticancer effects

15 studies10,000 participants

Supporting Studies (1)

PMID: 29099763 - Selenium and cancer risk: meta-analysis (2018)

ProbioticsB

Multi-strain probiotic (10-50 billion CFU) daily

Supports gut health during treatment; may reduce treatment-related GI side effects and support immunity

20 studies2,000 participants

Supporting Studies (1)

PMID: 29681486 - Probiotics in cancer patients: systematic review (2018)

How This Protocol Works

Simple Explanation

Cancer prevention and supportive care involves supporting the body's natural defenses while reducing factors that promote cancer development. This protocol focuses on evidence-based supplements that may help reduce cancer risk and support quality of life during and after cancer treatment. IMPORTANT: These supplements should complement, not replace, conventional cancer treatment. Always consult your oncologist before starting any supplements, as some may interact with cancer treatments.

•Vitamin D has extensive evidence linking deficiency to increased risk of colorectal, breast, and prostate cancers. Vitamin D regulates genes involved in cell growth, differentiation, and programmed cell death. The large VITAL trial showed vitamin D supplementation reduced cancer mortality, particularly in those who maintained adequate levels for several years. Most oncologists now recommend maintaining levels of 40-60 ng/mL.

•Omega-3 Fatty Acids have anti-inflammatory effects that may reduce cancer risk and help maintain healthy weight and muscle mass during treatment (cancer cachexia is a significant problem). They may also reduce inflammation associated with cancer progression. During treatment, omega-3s can help with appetite and nutritional status.

•Curcumin has been extensively studied for its anticancer properties in lab and animal studies, with growing human evidence. It works through multiple pathways—inhibiting NF-κB (a key inflammatory and cancer-promoting pathway), inducing apoptosis (programmed cell death) in cancer cells, and inhibiting tumor blood vessel growth. Clinical trials show it may enhance chemotherapy effectiveness and reduce side effects.

•Green Tea Extract (EGCG) contains catechins with demonstrated anticancer effects. Population studies show green tea drinkers have lower rates of certain cancers. EGCG inhibits tumor growth pathways and has been studied for preventing prostate cancer progression in men with precancerous changes.

•Medicinal Mushrooms (Reishi, Turkey Tail, Maitake) contain beta-glucans that stimulate immune cells (natural killer cells, macrophages) involved in cancer surveillance. Turkey Tail (PSK/PSP) is approved as an adjunct cancer therapy in Japan. These mushrooms may improve quality of life and immune function during conventional treatment.

•Selenium is essential for antioxidant enzymes. Some studies suggested selenium could reduce cancer risk, though the SELECT trial found no benefit (and possible harm at high doses) for prostate cancer. Current evidence suggests ensuring adequate (not excessive) selenium intake, primarily through diet.

•Probiotics support gut health, which is often compromised during cancer treatment. They may reduce antibiotic-associated diarrhea, radiation-induced GI symptoms, and support overall immune function.

Expected timeline: Prevention benefits require long-term use. Supportive care benefits may be noticeable within weeks of starting. Always inform your oncology team about all supplements.

Clinical Perspective

Cancer prevention and adjunctive care requires understanding both primary prevention (reducing cancer incidence) and tertiary prevention (improving outcomes in cancer patients). Mechanisms targeted include: oxidative stress reduction, inflammation modulation (NF-κB, COX-2, cytokines), immune surveillance enhancement, apoptosis induction, and angiogenesis inhibition. CRITICAL: All supplements must be reviewed by oncology team for potential interactions with chemotherapy, radiation, immunotherapy, and targeted agents.

•Vitamin D (B-grade): VDR expressed in most tissues; calcitriol regulates >200 genes including those controlling proliferation (p21, p27), differentiation, and apoptosis. Epidemiological data: inverse association between 25(OH)D levels and colorectal, breast, prostate cancer risk. VITAL trial (N=25,871): no reduction in cancer incidence but significant reduction in cancer mortality in intention-to-treat analysis, stronger with longer follow-up (PMID: 30415629). Meta-analysis supports mortality reduction (PMID: 31405204). Target 40-60 ng/mL; importance during treatment for bone health.

•Omega-3 Fatty Acids (B-grade): EPA/DHA compete with arachidonic acid, reducing pro-inflammatory eicosanoids. May inhibit COX-2 and NF-κB pathways. Systematic review: potential benefits for cancer-related weight loss, inflammation, and quality of life (PMID: 32025599). Also supports cardiovascular health (relevant as CV disease is leading cause of death in cancer survivors). 2-4g/day; may affect platelet function—discuss timing around surgery.

•Curcumin (B-grade): Pleiotropic anticancer mechanisms: inhibits NF-κB, STAT3, COX-2; induces apoptosis via mitochondrial pathway; inhibits angiogenesis (VEGF) and metastasis (MMPs). Phase I/II trials show safety with chemotherapy; may enhance efficacy of gemcitabine, docetaxel, others. Bioavailability critical—use enhanced formulations. Review: supports adjunctive use in multiple cancers (PMID: 25818808). CAUTION: May interact with certain chemotherapies—always clear with oncology.

•Green Tea Extract (EGCG) (B-grade): Catechins inhibit multiple kinases, induce cell cycle arrest, and trigger apoptosis. Inhibits proteasome function. Meta-analysis: reduced risk of breast, colorectal, and other cancers with regular consumption (PMID: 26092765). Clinical trials: slowed PSA rise in prostate cancer watchful waiting. High-dose extracts may cause hepatotoxicity—monitor LFTs. Avoid with bortezomib (may reduce efficacy).

•Medicinal Mushrooms (B-grade): Beta-glucans (polysaccharides) activate innate immunity via pattern recognition receptors (Dectin-1, CR3). Enhance NK cell activity, macrophage phagocytosis, dendritic cell function. Cochrane review of Ganoderma lucidum (Reishi): improved quality of life and immune parameters when combined with conventional treatment (PMID: 22972060). Turkey Tail (Trametes versicolor) PSK/PSP: approved adjunctive therapy in Japan; improves survival in gastric, colorectal cancer.

•Selenium (C-grade): Selenoproteins (glutathione peroxidases, thioredoxin reductases) provide antioxidant defense. SELECT trial: no prostate cancer prevention (and possible increased risk with high-dose supplementation) (PMID: 29099763). Current view: ensure adequacy (55-100mcg/day) but avoid excess. Brazil nuts are rich dietary source. May be more relevant in selenium-deficient populations.

•Probiotics (B-grade): Modulate gut microbiome, which influences immune function and potentially tumor microenvironment. Systematic review: reduce chemotherapy-induced diarrhea, radiation enteritis, may improve immune parameters (PMID: 29681486). Strain selection matters. CAUTION: Avoid live cultures in severely immunocompromised/neutropenic patients.

Biomarker targets: 25(OH)D (40-60 ng/mL), inflammatory markers (hsCRP, ESR), immune parameters (lymphocyte subsets if indicated), nutritional status (albumin, prealbumin), tumor markers as appropriate.

Protocol notes: ALWAYS coordinate with oncology team. Timing relative to treatment matters—some supplements may need to be held around chemotherapy or radiation. Antioxidants during radiation therapy remain controversial—some oncologists prefer avoidance. Curcumin, green tea may interact with certain drugs via CYP enzymes. Focus on evidence-based lifestyle: plant-rich diet, regular exercise, healthy weight, limited alcohol, no tobacco. Consider integrative oncology consultation. Quality of supplements critical—third-party testing (NSF, USP). Address symptoms: fatigue, nausea, cachexia, neuropathy have specific supportive interventions.

View All Protocols